Toxins stay in smokers' houses for months

For smokers, physicians often recommend one of the best ways to immediately improve their health: stop smoking. But for the smokers (and the nonsmokers they live with), it could take months to reap the full benefits of eliminating tobacco use, reported the New York Times.

That’s because, as a new study from the journal Tobacco Control shows, toxins from smoking remain in smokers’ homes for up to six months after they quitand maybe longer.

The researchers examined the homes of 65 smokers in the process of quitting. And while some cigarette toxins disappeared from their houses as soon as the cigarettes themselves did, others remained. Such toxins proved even more insidious than the tangible smoke because they were invisible and unexpected.

When the study participants smoked, particles of smoke, nicotine, tobacco and other compounds seeped into the physical parts of their homes. The Times pointed out “carpets, upholstery, pillows, blankets, clothes, even wallpaper and ceiling tiles” as examples. The toxins could continue to poison the residents of the house even after the smoking had stopped.

In fact, some were still on hard surfaces and in the dust particles of the house at least six months after the smoker had quit. And most tellingly, the toxins could still be detected in the nonsmokers’ urine after six months, meaning it could be harmful for nonsmokers to live in a house where someone had previously smoked.

Check out the New York Times to see why people often feel their quitting smoking is enough to get rid of its dangerous effects right away. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.